Parametric Portfolio Associates LLC increased its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 34.5% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 424,124 shares of the medical equipment provider’s stock after acquiring an additional 108,801 shares during the period. Parametric Portfolio Associates LLC owned about 0.15% of Hologic worth $19,247,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of HOLX. Mutual of America Capital Management LLC boosted its position in shares of Hologic by 1.3% during the 1st quarter. Mutual of America Capital Management LLC now owns 34,720 shares of the medical equipment provider’s stock valued at $1,477,000 after acquiring an additional 453 shares in the last quarter. Pacer Advisors Inc. boosted its position in shares of Hologic by 4.3% during the 1st quarter. Pacer Advisors Inc. now owns 8,134 shares of the medical equipment provider’s stock valued at $346,000 after acquiring an additional 337 shares in the last quarter. Neuberger Berman Group LLC boosted its position in shares of Hologic by 1,735.5% during the 1st quarter. Neuberger Berman Group LLC now owns 289,874 shares of the medical equipment provider’s stock valued at $12,334,000 after acquiring an additional 274,081 shares in the last quarter. OppenheimerFunds Inc. boosted its position in shares of Hologic by 31.5% during the 1st quarter. OppenheimerFunds Inc. now owns 377,892 shares of the medical equipment provider’s stock valued at $16,080,000 after acquiring an additional 90,435 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its position in shares of Hologic by 1.3% during the 1st quarter. Principal Financial Group Inc. now owns 432,748 shares of the medical equipment provider’s stock valued at $18,413,000 after acquiring an additional 5,669 shares in the last quarter. Institutional investors and hedge funds own 96.38% of the company’s stock.

Hologic, Inc. (HOLX) opened at 37.78 on Thursday. The company has a market capitalization of $10.60 billion, a P/E ratio of 14.07 and a beta of 0.91. Hologic, Inc. has a 52 week low of $35.15 and a 52 week high of $46.80. The firm has a 50 day moving average of $37.79 and a 200-day moving average of $42.16.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share for the quarter, beating analysts’ consensus estimates of $0.49 by $0.01. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The company had revenue of $806.10 million for the quarter, compared to the consensus estimate of $799.70 million. During the same period last year, the company posted $0.51 EPS. The firm’s quarterly revenue was up 12.4% compared to the same quarter last year. On average, analysts forecast that Hologic, Inc. will post $2.01 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Parametric Portfolio Associates LLC Acquires 108,801 Shares of Hologic, Inc. (HOLX)” was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/parametric-portfolio-associates-llc-acquires-108801-shares-of-hologic-inc-holx/1609844.html.

Several analysts have recently weighed in on the stock. Royal Bank Of Canada reiterated a “sector perform” rating and set a $45.00 target price (down from $50.00) on shares of Hologic in a research report on Wednesday, August 9th. BidaskClub lowered shares of Hologic from a “hold” rating to a “sell” rating in a research report on Wednesday, August 9th. Barclays PLC reiterated an “equal weight” rating and set a $51.00 target price (down from $53.00) on shares of Hologic in a research report on Wednesday, August 9th. Needham & Company LLC reiterated a “buy” rating on shares of Hologic in a research report on Tuesday, August 1st. Finally, Zacks Investment Research lowered shares of Hologic from a “hold” rating to a “sell” rating in a research report on Tuesday. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and nine have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $48.38.

In other news, Director Lawrence M. Levy sold 7,139 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $39.04, for a total value of $278,706.56. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Elaine Ullian sold 6,902 shares of the firm’s stock in a transaction that occurred on Thursday, August 3rd. The shares were sold at an average price of $40.12, for a total transaction of $276,908.24. Following the completion of the transaction, the director now owns 23,810 shares of the company’s stock, valued at approximately $955,257.20. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 18,745 shares of company stock worth $768,189. 0.79% of the stock is currently owned by corporate insiders.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.